deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03301168

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders

Sponsor: Bellicum Pharmaceuticals

Conditions Acute Lymphoblastic Leukemia Anemia, Aplastic Cytopenia Hemoglobinopathy in Children Leukemia, Acute Myeloid (AML), Child Lymphoma, Non-Hodgkin Myelodysplastic Syndromes Osteopetrosis Primary Immune Deficiency Disorder
Interventions BPX-501 T cells Rimiducid
Updated 18 times since 2017 Last updated: Jul 10, 2022 Started: Apr 30, 2014 Primary completion: May 11, 2021 Completion: May 31, 2034
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Acute Lymphoblastic Leukemia and Anemia, Aplastic, this trial is ongoing. The trial is conducted by Bellicum Pharmaceuticals and has accumulated 18 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Nov 2020 · 12 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2022 · 20 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Sep 2022 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jan 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 13 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Nov 2019 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Aug 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. May 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Feb 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Oct 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  12. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

  13. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bellicum Pharmaceuticals
Data source: Bellicum Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations